Ruxolitinib treatment and risk of B-cell lymphomas in myeloproliferative neoplasms

Am J Hematol. 2019 Jul;94(7):E185-E188. doi: 10.1002/ajh.25489. Epub 2019 May 1.

Authors

Elisa Rumi^{1

2}, Silvia Zibellini¹, Emanuela Boveri³, Chiara Cavalloni², Roberta Riboni³, Ilaria Carola Casetti², Michele Ciboddo², Chiara Trotti², Cristina Favaron², Daniela Pietra¹, Chiara Candido¹, Virginia Valeria Ferretti², Mario Cazzola^{1

2}, Luca Arcaini^{1

2}

Affiliations

¹ Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
² Department of Molecular Medicine, University of Pavia, Pavia, Italy.
³ Anatomic Pathology Section, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy.

PMID: 30972817
DOI: 10.1002/ajh.25489

No abstract available

Publication types

Clinical Trial
Letter
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't

MeSH terms

Female
Follow-Up Studies
Humans
Lymphoma, B-Cell* / drug therapy
Lymphoma, B-Cell* / mortality
Male
Myeloproliferative Disorders* / drug therapy
Myeloproliferative Disorders* / mortality
Nitriles
Pyrazoles / administration & dosage*
Pyrimidines
Risk Factors

Substances

Nitriles
Pyrazoles
Pyrimidines
ruxolitinib